Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 21

1530P - Health-related quality of life (hrqol) in patients with claudin-18 isoform 2-positive (CLDN18.2+) locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma: Results from SPOTLIGHT and GLOW

Date

21 Oct 2023

Session

Poster session 21

Topics

Supportive Care and Symptom Management;  Targeted Therapy;  Immunotherapy

Tumour Site

Gastric Cancer;  Gastro-Oesophageal Junction Cancer

Presenters

Florian Lordick

Citation

Annals of Oncology (2023) 34 (suppl_2): S852-S886. 10.1016/S0923-7534(23)01930-0

Authors

F. Lordick1, E. Van Cutsem2, K. Shitara3, R. Xu4, J.A. Ajani5, M.A. Shah6, M. Oh7, A. Ganguli8, S. Rhoten9, P. Bhattacharya10, M. Matsangou11, J.W. Park12, Y. Kang13

Author affiliations

  • 1 Department Of Medicine And University Cancer Center Leipzig, University of Leipzig Medical Center, 04103 - Leipzig/DE
  • 2 Digestive Oncology, University Hospitals Gasthuisberg, Leuven, and KULeuven, Leuven/BE
  • 3 Department Of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa/JP
  • 4 Department Of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou/CN
  • 5 Gi Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston/US
  • 6 Medical Oncology & Hematology, Weill Cornell Medical College, New York/US
  • 7 Heor, Medical Affairs, Astellas Pharma Global Development, Inc., Northbrook/US
  • 8 Heor, Astellas Pharma Global Development, Inc., Northbrook/US
  • 9 Patient Centered Solutions, IQVIA, San Francisco/US
  • 10 Development Division, Astellas Pharma Global Development, Inc., Northbrook/US
  • 11 Development Therapeutic Area- Oncology, Astellas Pharma Global Development, Inc., Northbrook/US
  • 12 Biostatistics, Astellas Pharma Global Development, Inc., Northbrook/US
  • 13 Department Of Oncology, Asan Medical Center, University of Ulsan, Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1530P

Background

In the randomized, double-blind, global SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) trials, first-line zolbetuximab + chemo (mFOLFOX6 [SPOTLIGHT]; CAPOX [GLOW]) showed improved PFS (SPOTLIGHT, HR 0.75 [95% CI 0.60, 0.94], P = 0.0066; GLOW, HR 0.69 [95% CI 0.54, 0.87], P = 0.0007) and OS (SPOTLIGHT, HR 0.75 [95% CI 0.60, 0.94], P = 0.0053; GLOW, HR 0.77 [95% CI 0.62, 0.97], P = 0.0118) compared with placebo + chemo in patients with CLDN18.2+, HER2−, LA unresectable or mG/GEJ adenocarcinoma at data cutoff. We present key patient-reported outcome (PRO) findings from these trials.

Methods

Patients completed the EORTC QLQ-C30 and QLQ-OG25 at screening, every 3 weeks on treatment, at discontinuation, and 30 and 90 days thereafter. Changes in scores from baseline, time to confirmed deterioration (TTCD), and time to definitive deterioration (TTDD) in PROs based on literature thresholds were evaluated. Least square mean (LSM) changes from baseline were summarized descriptively. TTCD and TTDD were assessed by Kaplan-Meier estimates and Cox hazard models.

Results

Table describes the LSM changes from baseline for SPOTLIGHT (N = 565) and GLOW (N = 507). No clinically meaningful deteriorations in global health status and quality of life (GHS/QoL), physical functioning (PF), abdominal pain and discomfort, or nausea/vomiting (N/V) were observed. Overall TTCD and TTDD results were similar between arms in both studies.

Table: 1530P

Zolbetuximab + chemo LSM (standard error [SE]) Placebo + chemo LSM (SE) Zolbetuximab vs placebo arms LSM (95% CI) P value
SPOTLIGHT Cycle 9 Day 1 (N = 283) (N = 282)
GHS/QoL 1.65 (1.60) 4.20 (1.77) -2.54 (-7.02, 1.93) 0.263
PF -5.68 (1.77) 0.34 (1.88) -6.02 (-10.85, -1.19) 0.015
Pain -6.85 (1.86) -9.12 (2.08) 2.27 (-2.97, 7.51) 0.394
N/V -3.38 (1.64) -2.31 (1.80) -1.07 (-5.61, 3.47) 0.642
GLOW Cycle 17 Day1 (N = 254) (N = 253)
GHS/QoL -0.04 (2.43) -5.55 (2.89) 5.51 (-1.82, 12.84) 0.139
PF -2.05 (1.88) -2.93 (2.19) 0.88 (-4.67, 6.43) 0.753
Pain -5.39 (2.32) -7.27 (2.88) 1.88 (-5.30, 9.07) 0.604
N/V -0.95 (1.89) 2.85 (2.31) -3.79 (-9.57, 1.98) 0.192

Conclusions

There were not overall clinical HRQoL differences between patients in the zolbetuximab and placebo arms. Zolbetuximab + chemo improved clinical outcomes without negatively affecting HRQoL in key PROs in both SPOTLIGHT and GLOW.

Clinical trial identification

NCT03653507.

Editorial acknowledgement

Medical writing support, conducted in accordance with Good Publication Practice (GPP 2022) and the International Committee of Medical Journal Editors (ICMJE) guidelines, was provided by Ann Ferguson, PhD, of Oxford PharmaGenesis Inc., and was funded by Astellas Pharma Inc.

Legal entity responsible for the study

Astellas Pharma Inc.

Funding

Astellas Pharma Inc.

Disclosure

F. Lordick: Financial Interests, Personal, Advisory Board: Amgen, Astellas, BMS, Bayer, BeiGene, Biontech, Eli Lilly, Elsevier, MSD, Novartis, Roche, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Eli Lilly, Imedex, Incyte, MSD, MedUpdate, Medscape, Merck, Roche, Servier, StreamedUp!, Daiichi Sankyo, Novartis, Art Tempi; Financial Interests, Personal, Writing Engagement: Deutscher Ärzteverlag, Iomedico, Springer-Nature; Financial Interests, Institutional, Research Grant: BMS, Gilead. E. Van Cutsem: Financial Interests, Personal, Advisory Board: AbbVie, ALX, Amgen, Array, Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GSK, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seattle Genetics, Servier, Takeda, Terumo, Taiho, Zymeworks; Financial Interests, Institutional, Research Grant: Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, Servier. K. Shitara: Financial Interests, Personal, Advisory Board: Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical, MSD, Taiho, Novartis, AbbVie, GSK, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Guardant Health Japan Corp, Astellas Pharma Inc.; Financial Interests, Personal, Invited Speaker: Janssen Pharmaceutical K.K.; Financial Interests, Institutional, Research Grant: Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho, Chugai Pharmaceutical, MSD, Eisai, Amgen. R. Xu: Financial Interests, Personal, Invited Speaker: BMS, MSD; Financial Interests, Personal, Advisory Board: Henrui, BeiGene, Astellas, Merck, Junshi. J.A. Ajani: Financial Interests, Personal, Research Funding: Astellas Pharma Inc.; Financial Interests, Research Funding: Turning Point Therapeutics, Inc., Bristol Myers Squibb, Merck, Taiho Pharmaceutical, Delta-Fly Pharma, Inc., Roche, ProLynx Inc, Zymeworks; Financial Interests, Research Grant: Daiichi Sankyo, Leap Therapeutics, Inc., Gilead Sciences, Inc., Lanova Pharma; Financial Interests, Speaker, Consultant, Advisor: Bristol Myers Squibb, Merck, Astellas Pharma Inc., Amgen, Taiho Pharmaceutical, Zymeworks, BeiGene, AstraZeneca, Daiichi Sankyo, Bayer, GRAIL, Novartis, Geneos, Servier Laboratories, Gilead Sciences, Inc.; Financial Interests, Other, receiving support for travel and/or meeting attendance: Daiichi Sankyo, Bristol Myers Squibb, Merck, BeiGene. M.A. Shah: Financial Interests, Personal, Research Funding: Astellas Pharma Inc., Merck, Bristol Myers Squibb, Oncolys BioPharma; Financial Interests, Personal, Leadership Role: ASCO Leadership Council. M. Oh; A. Ganguli; P. Bhattacharya; M. Matsangou; J.W. Park: Financial Interests, Personal, Full or part-time Employment: Astellas Pharma Global Development, Inc. S. Rhoten: Financial Interests, Personal, Full or part-time Employment: IQVIA. Y. Kang: Financial Interests, Personal, Advisory Board: ALX Oncology, Zymeworks, Amgen, Novartis, MacroGenics, Daehwa, Blueprint, Surface Oncology, BMS, Merck, Roche, LISCure.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.